S

Southern Clinical Research | Zachary, LA

Research site

(Unclaimed)

Location

4867 West Park Drive, Zachary, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Obicetrapib

sodium

Selonsertib

BAY 2433334

GS-4997

Finerenone

Elinzanetant

Inclisiran

BAY3427080

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 14 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Infant Formula and Toddler Drink Feeding Study

The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months...

Active, not recruiting

Growth

Other: Human Milk

Other: Human Milk Toddler Drink

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Dyslipidemias

Drug: Placebo

Drug: Obicetrapib

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg